Men's Health News

RSS

Combination therapy before prostate removal may prevent recurrence of cancer

Researchers in the Oregon Health & Science University Knight Cancer Institute and the Portland Veterans Affairs Medical Center have found a combination of radiation therapy and chemotherapy given before prostate removal is safe and may have the potential to reduce cancer recurrence and improve patient survival.

4 Nov 2009

Patients who have an undetectable level of PSA after therapy have good chance of being cured

Fox Chase Cancer Center researchers report that radiation therapy alone can reduce prostate specific antigen (PSA) levels below detectable amounts in prostate cancer patients. Patients who have an undetectable level of PSA after therapy have less chance of biochemical failure than other patients and a good chance of being cured.

4 Nov 2009

AUA clarifes recommendations on prostate cancer testing with PSA test and DRE

The American Urological Association (AUA) is aware of recent news reports disparaging prostate cancer testing. We are concerned that these reports are causing significant confusion for patients and we wish to clarify our recommendations on prostate cancer testing with the prostate-specific antigen (PSA) test and digital rectal exam (DRE). The AUA strongly supports early prostate cancer detection and feels it is in a man's best interest to consider being tested for prostate cancer.

4 Nov 2009

Radiation treatment as effective and as safe in reducing the risk of prostate cancer from returning

A shorter, five-week course of radiation treatment that delivers higher doses of radiation in fewer sessions, known as hypofractionation, appears to be just as effective and as safe in reducing the risk of prostate cancer from returning as standard radiation therapy, yet is delivered in two-and-a-half weeks less time, according to interim results of a randomized study presented November 4, 2009, at the 51st Annual Meeting of the American Society for Radiation Oncology (ASTRO).

4 Nov 2009

Men with lower cholesterol less likely to develop high-grade prostate cancer

Men with lower cholesterol are less likely than those with higher levels to develop high-grade prostate cancer - an aggressive form of the disease with a poorer prognosis, according to results of a Johns Hopkins collaborative study.

4 Nov 2009

Blood vessels good indicators of prostate cancer behavior

A diagnosis of prostate cancer raises the question for patients and their physicians as to how the tumor will behave. Will it grow quickly and aggressively and require continuous treatment, or slowly, allowing therapy and its risks to be safely delayed?

4 Nov 2009

Early tolerance of proton therapy excellent in prostate cancer patients

Proton beam therapy can be safely delivered to men with prostate cancer and has minimal urinary and rectal side effects, according to a study presented November 2, 2009, at the American Society for Radiation Oncology's 51st Annual Meeting in Chicago.

3 Nov 2009

Extra dose of proton radiation therapy reduces prostate cancer recurrences

Men who receive a "boost" of proton therapy after receiving a standard course of X-ray radiation therapy have fewer recurrences of their prostate cancer compared to men who did not receive the extra dose of proton radiation, according to a first-of-its-kind study presented November 2, 2009, at the American Society for Radiation Oncology's 51st Annual Meeting in Chicago.

3 Nov 2009

NIA funds national Testosterone Trial, Penn Medicine to lead

Penn Medicine will lead a new national $45 million clinical trial to test whether testosterone therapy can favorably affect certain conditions affecting older men. Low serum testosterone may contribute to a number of problems affecting older men, including decreased ability to walk, loss of muscle mass and strength, decreased vitality, decreased sexual function, impaired cognition, cardiovascular disease and anemia. While testosterone normally decreases with age, in some men, low levels of testosterone may contribute to these debilitating conditions.

2 Nov 2009

Dendreon submits an amended BLA for PROVENGE active cellular immunotherapy

Dendreon Corporation today announced that it has completed the submission of the amended Biologics License Application (BLA) for PROVENGE® (sipuleucel-T), the Company's lead investigational product, to the U.S. Food and Drug Administration (FDA). Dendreon is seeking licensure for PROVENGE for men with metastatic castrate-resistant prostate cancer (CRPC).

2 Nov 2009

FDA issues a Complete Response Letter for GTx' toremifene NDA

GTx, Inc. today announced that it has received a Complete Response Letter issued by the United States Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for toremifene 80 mg to reduce fractures in men with prostate cancer receiving androgen deprivation therapy (ADT).

2 Nov 2009

Married men more likely to seek professional healthcare compared to single counterparts

According to a Mintel survey of adult men, those who are married are more likely to have had a physical with a registered physician within the past year compared to their single counterparts (55% versus 35%).

31 Oct 2009

FDA-approved drug PEG-ADA shows positive results in relieving major complication of priapism

Thousands of men are afflicted with an embarrassing and painful condition that triggers spontaneous, long-lasting erections. There are limited treatment options, but a solution could be on the way thanks to new research at The University of Texas Health Science Center at Houston.

31 Oct 2009

Researchers report an epidemic of sexually-transmitted HCV infection among HIV-infected men in NY City

Researchers in New York City are reporting their work uncovering a new epidemic of hepatitis C virus (HCV) infection among men-who-have-sex-with-men (MSM) who have HIV infection.

30 Oct 2009

Research provides new insight on gene fusion, a phenomenon known to cause prostate cancer

Researchers at the University of Michigan Comprehensive Cancer Center have discovered what leads to two genes fusing together, a phenomenon that has been shown to cause prostate cancer to develop.

30 Oct 2009

Researchers find link between foreskin and HIV infection

Randomized clinical trials conducted by researchers in Rakai, Uganda, have revealed a link between the size of foreskin surface area and the risk of male HIV acquisition.

28 Oct 2009

Adenosine deaminase enzyme therapy offers hope for priapism

For men coping with painful erections lasting for long periods of time, or priapism, new research published online in The FASEB Journal (http://www.fasebj.org) offers hope. That's because researchers from the United States and China show that the enzyme adenosine deaminase may prevent priapism from progressing to penile fibrosis, a condition associated with the build up of scar tissue and eventual impotence.

27 Oct 2009

Japanese Ministry approves marketing of AMS800 Artificial Urinary Sphincter in Japan

American Medical Systems®, a leading provider of world-class devices and therapies for both male and female pelvic health, today announced that it has received clearance from the Japanese Ministry of Health, Labor and Welfare (MHLW) to market and distribute its AMS 800 Artificial Urinary Sphincter (AUS) in Japan, effective September 7, 2009.

23 Oct 2009

New tools needed to identify men and women at risk for the most aggressive cancers

Twenty years of screening for breast and prostate cancer - the most diagnosed cancer for women and men - have not brought the anticipated decline in deaths from these diseases, argue experts from the University of California, San Francisco and the University of Texas Health Science Center at San Antonio in an opinion piece published in the "Journal of the American Medical Association."

21 Oct 2009

Testicular cancer survivors at risk of effective treatment

Testicular cancer survivors can face an increased risk of long-term illness, not because of the malignancy, but the highly effective treatment they receive, according to a study in the urology journal BJUI.

20 Oct 2009

Men's Health News

Combination therapy before prostate removal may prevent recurrence of cancer

Patients who have an undetectable level of PSA after therapy have good chance of being cured

AUA clarifes recommendations on prostate cancer testing with PSA test and DRE

Radiation treatment as effective and as safe in reducing the risk of prostate cancer from returning

Men with lower cholesterol less likely to develop high-grade prostate cancer

Blood vessels good indicators of prostate cancer behavior

Early tolerance of proton therapy excellent in prostate cancer patients

Extra dose of proton radiation therapy reduces prostate cancer recurrences

NIA funds national Testosterone Trial, Penn Medicine to lead

Dendreon submits an amended BLA for PROVENGE active cellular immunotherapy

FDA issues a Complete Response Letter for GTx' toremifene NDA

Married men more likely to seek professional healthcare compared to single counterparts

FDA-approved drug PEG-ADA shows positive results in relieving major complication of priapism

Researchers report an epidemic of sexually-transmitted HCV infection among HIV-infected men in NY City

Research provides new insight on gene fusion, a phenomenon known to cause prostate cancer

Researchers find link between foreskin and HIV infection

Adenosine deaminase enzyme therapy offers hope for priapism

Japanese Ministry approves marketing of AMS800 Artificial Urinary Sphincter in Japan

New tools needed to identify men and women at risk for the most aggressive cancers

Testicular cancer survivors at risk of effective treatment

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest News